Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. - Wikidata - awgldk - TriplyDB

Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.

Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.

http://www.wikidata.org/entity/Q46828751

about

Therapeutic rescue of misfolded mutants: validation of primary high throughput screens for identification of pharmacoperone drugs The Trafficking of the Water Channel Aquaporin-2 in Renal Principal Cells-a Potential Target for Pharmacological Intervention in Cardiovascular Diseases Pharmacoperones: a new therapeutic approach for diseases caused by misfolded G protein-coupled receptors Pharmacological chaperoning: a primer on mechanism and pharmacology Emerging novel concept of chaperone therapies for protein misfolding diseases A novel therapeutic effect of statins on nephrogenic diabetes insipidus Protein trafficking defects in inherited kidney diseases How genetic errors in GPCRs affect their function: Possible therapeutic strategies A phenotypic high throughput screening assay for the identification of pharmacoperones for the gonadotropin releasing hormone receptor Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs.Transitioning pharmacoperones to therapeutic use: in vivo proof-of-principle and design of high throughput screens.Using pharmacological chaperones to restore proteostasis Functional characterization of vasopressin type 2 receptor substitutions (R137H/C/L) leading to nephrogenic diabetes insipidus and nephrogenic syndrome of inappropriate antidiuresis: implications for treatments.Chaperoning G protein-coupled receptors: from cell biology to therapeutics A small molecule agonist THIQ as a novel pharmacoperone for intracellularly retained melanocortin-4 receptor mutants.Rare inherited kidney diseases: challenges, opportunities, and perspectives.Restoration of testis function in hypogonadotropic hypogonadal mice harboring a misfolded GnRHR mutant by pharmacoperone drug therapy.High-throughput screen for pharmacoperones of the vasopressin type 2 receptor Novel mutation in the AVPR2 gene in a Danish male with nephrogenic diabetes insipidus caused by ER retention and subsequent lysosomal degradation of the mutant receptor.Escorts take the lead molecular chaperones as therapeutic targets Pharmacological chaperones for misfolded gonadotropin-releasing hormone receptors Assay strategies for identification of therapeutic leads that target protein trafficking Pharmacological chaperone therapy for Fabry disease A Rare Case of Congenital Diabetes Insipidus.Vasopressin receptor antagonists and their role in clinical medicine.Partial nephrogenic diabetes insipidus caused by a novel AQP2 variation impairing trafficking of the aquaporin-2 water channel.The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology.Identification of Potential Pharmacoperones Capable of Rescuing the Functionality of Misfolded Vasopressin 2 Receptor Involved in Nephrogenic Diabetes Insipidus Signaling Modification by GPCR Heteromer and Its Implication on X-Linked Nephrogenic Diabetes Insipidus.Refolding of misfolded mutant GPCR: post-translational pharmacoperone action in vitro.Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment.Conivaptan: a step forward in the treatment of hyponatremia?Agonist-independent interactions between beta-arrestins and mutant vasopressin type II receptors associated with nephrogenic syndrome of inappropriate antidiuresis.Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.Enhancement of the surface expression of G protein-coupled receptors.Mutations in G protein-coupled receptors that impact receptor trafficking and reproductive function.Chaperone-like effects of cell-permeant ligands on opioid receptors.Pediatric disorders of water balance.Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.Genetic testing in renal disease.

P2860

Q21089948-238F6B59-82EB-4317-B804-50E41EC20B8B Q26768170-021FAC98-4819-41F3-B2A5-FC8581CFDF2A Q26992276-909BE81B-3115-44DD-8CA0-3284C81DAF23 Q27001695-65A89D84-EE8A-4198-8CA6-00926AA4888D Q27002907-7CFB33F5-7351-454E-B33F-C7CE8BD85233 Q27005638-0ECF1A90-6EC5-47CE-A2B6-17A1216045F8 Q27012909-BC7989D1-A273-4D44-99A0-AEA9CA08FFD1 Q28646207-D306C580-02D8-4E25-A21A-2DBAE58A2635 Q33629937-566FC59C-2EB8-486C-888B-147BED6D9557 Q33699210-F5BAB694-DFF6-42E6-BEB4-7095036F569F Q33717398-06BA5091-3C7C-4278-A410-60817A71CD9D Q33804655-9AC7CED5-0C42-494C-94FE-3E8A742D759A Q33862041-859A2FD7-90A8-460B-ACB7-504B3595F453 Q33927508-2FCD622C-FC42-475A-A7CD-41376CDD9990 Q33970155-C2A22AAC-7AC7-4229-9AC0-0D4EC84368C8 Q34054113-D1633013-DCA8-4CBD-8438-39F0B1557DF2 Q34390847-3DC4649C-18F8-4EA7-8F9B-013DD9511224 Q34703957-66657F1A-E487-4813-BF7E-7DAEB8C11955 Q35012380-B5CBE7AB-E527-4C16-8B0A-21C4A95CAE46 Q35075365-033E92C4-B64C-4C41-82C5-92BEE3789DB7 Q35606973-0C131752-AEBF-4C17-8B31-4CFDBB0CE286 Q35661403-CFB1C5A5-22BC-4233-9B7D-A76092E16961 Q35755438-05A6D609-C2AD-45E4-910A-3C8ED5787A24 Q35824173-33C05618-E313-4E7E-B591-4E7ED0BA8C58 Q35856033-82A558F7-5744-4CAD-B7F8-D94E67805E72 Q35881045-9A82546F-C7D5-4959-A719-38340CD9F550 Q36003378-37C27F65-5F47-4902-942D-90503AAE9042 Q36046576-B65E185C-A741-4738-A1D6-9B5E30C74022 Q36138589-56CEF5F6-1E51-480E-95C7-3AB8F0D34CC5 Q36316416-F83D91C3-731E-4C3E-9580-72308D04AF2B Q36724058-DE9ACA76-8878-403F-B449-874A52FB8482 Q36823541-60D32897-AD0A-45BD-9738-C2F375C4CB91 Q37155408-CE76552D-8916-47F6-B9AC-C20C44F6B9E7 Q37274407-9A09CE73-7287-4D3D-B3CC-AAA41EE547A6 Q37316198-7844D7E7-9807-419E-9EA6-73A315313EFF Q37351126-527B2216-6A38-45E4-B25F-9BEA2624E65C Q37410011-8E3AFE30-FC8D-4DBC-BAD0-976C80E1E77A Q37640345-F3810552-75A5-4DAD-95FA-656BDED63BD4 Q37668227-2D1F58FE-A5E8-4820-9886-95B1C66DC07E Q37880653-4270DFD2-C785-4E1A-A694-438E7540CAB4

P2860

Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus.

http://www.wikidata.org/entity/Q46828751

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.

@en

Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.

@nl

type

label

Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.

@en

Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.

@nl

prefLabel

Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.

@en

Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.

@nl

P1433

Q46828751-52775F05-563F-44A4-B1FA-462383C04FF2

P1476

Q46828751-2C3865E6-14A6-48FA-B079-D68C734E858B

P2093

Q46828751-1B075750-D941-4E5B-B7DC-0686D0EA9459

Q46828751-219966CC-A687-4215-B74C-BB474B2BABCB

Q46828751-79CA61BE-91B9-4684-A935-1E353D27C539

Q46828751-94187B58-50B4-4072-921C-0400C37E809D

Q46828751-967F21AD-835F-4F3A-B3E6-A04D5E33DCE2

Q46828751-A367BB86-5560-4736-8FD2-47A50614D9E3

Q46828751-BDDE4F64-F5FB-4C44-AF40-08DD4A0C858A

Q46828751-E7F0D8E9-353F-4AE4-8C2C-3AF4E77D6723

Q46828751-F00A9052-0DD9-4BCC-923A-0E89ED03E22A

Q46828751-F75E5E73-0433-405E-B7E3-DE31B896E9AA

P304

Q46828751-70D32DEA-3693-4320-88D2-D5FB06B07331

P31

Q46828751-8B3BC648-2EF3-4ECC-BA6C-EB508154B3B2

P356

Q46828751-1A3EF583-EBFD-45EC-8B63-EE5628B0CA29

P433

Q46828751-937C6FAB-C974-40A5-8BC9-E686BC13A44E

P478

Q46828751-769BEF42-80DD-4C32-A643-D934AB91381E

P50

Q46828751-E3E5ED47-8F1B-4081-9546-FF532025D674

P577

Q46828751-F4559B23-F2F0-4289-9621-796B2FAC6AD3

P698

Q46828751-AFE42181-5945-449B-BEEF-3047569DC4C8

P921

Q46828751-1D5D9573-6C05-4F0E-B88E-387654143666

Q46828751-6388A6E8-F71B-4D71-91D0-61E5AE8AA388

P356

P1433

Journal of the American Society of Nephrology

P1476

Pharmacologic chaperones as a ...... ephrogenic diabetes insipidus.

@en

P2093

Alexandro Zarruk

http://www.w3.org/2001/XMLSchema#string

Ali Salahpour

http://www.w3.org/2001/XMLSchema#string

André Laperrière

http://www.w3.org/2001/XMLSchema#string

Daniel G Bichet

http://www.w3.org/2001/XMLSchema#string

Jean-Pierre Morello

http://www.w3.org/2001/XMLSchema#string

Marie-Françoise Arthus

http://www.w3.org/2001/XMLSchema#string

Michèle Lonergan

http://www.w3.org/2001/XMLSchema#string

Nicolas Debrand

http://www.w3.org/2001/XMLSchema#string

Rémi Brouard

http://www.w3.org/2001/XMLSchema#string

Virginie Bernier

http://www.w3.org/2001/XMLSchema#string

P304

232-243

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2005080854

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-11-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16319185

http://www.w3.org/2001/XMLSchema#string

P921

molecular chaperones